- Home
- PHAT
as 12-18-2024 10:41am EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 539.5M | IPO Year: | 2019 |
| Target Price: | $23.00 | AVG Volume (30 days): | 992.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.07 - $19.71 | Next Earning Date: | 11-07-2024 |
| Revenue: | $26,270,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 7622.43% | Revenue Growth (next year): | 236.87% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parikh Asit | PHAT | Director | Dec 13 '24 | Buy | $8.12 | 10,000 | $81,248.00 | 75,500 | |
| KARBE FRANK | PHAT | Director | Dec 13 '24 | Buy | $7.93 | 12,500 | $99,083.75 | 57,000 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
Insider Monkey
6 days ago
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?
MT Newswires
7 days ago
Phathom Pharmaceuticals Files US FDA Petition to Seek Voquezna Exclusivity Period
GlobeNewswire
7 days ago
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
Zacks
12 days ago
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
Zacks
a month ago
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
GuruFocus.com
a month ago
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
MT Newswires
a month ago
Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens
Zacks
a month ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.